XML 20 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Operating activities      
Net loss $ (158,899,000) $ (95,154,000) $ (112,444,000)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 3,621,000 3,244,000 2,257,000
Write-off of assets in progress     862,000
Loss (gain) on disposal of property and equipment 98,000 (10,000) 91,000
Accretion of discounts and amortization of premiums on marketable securities (1,559,000) (193,000) 178,000
Reversal of deferred rent upon lease amendment   (209,000)  
Cash-settled portion of stock compensation expense 0 0 602,000
Stock compensation expense 23,478,000 14,917,000 14,126,000
Cost of sales - amortization of intangible assets 10,862,000 1,194,000  
Non-cash interest expense 2,755,000    
Changes in operating assets and liabilities:      
Accounts and other receivables (2,850,000) 488,000 52,000
Inventories, net (18,710,000) (312,000)  
Prepaid expenses and other current assets (2,405,000) (1,830,000) 560,000
Other assets (3,706,000) (936,000) (103,000)
Accounts payable 3,417,000 (1,915,000) 1,181,000
Accrued liabilities and other long term liabilities 12,597,000 3,198,000 (11,759,000)
Deferred revenues     (2,654,000)
Net cash used in operating activities (131,301,000) (77,518,000) (107,051,000)
Investing activities      
Acquisition of technology licenses (11,000,000)    
Purchases of marketable securities (213,804,000) (227,672,000) (126,754,000)
Proceeds from maturities of marketable securities 284,457,000 119,638,000 220,760,000
Purchases of property and equipment, net (4,187,000) (669,000) (7,757,000)
Net cash provided by (used in) investing activities 55,466,000 (108,703,000) 86,249,000
Financing activities      
Proceeds from long-term debt, net 99,000,000    
Proceeds from issuances of common stock, net   185,936,000  
(Tax withholding) proceeds from exercise of stock options and restricted stock awards, net (523,000) 1,613,000 (84,000)
Proceeds from Employee Stock Purchase Plan 594,000 293,000 615,000
Net cash provided by financing activities 99,071,000 187,842,000 531,000
Effect of exchange rate changes on cash, cash equivalents and restricted cash (482,000) 701,000 (259,000)
Net increase (decrease) in cash, cash equivalents and restricted cash 22,754,000 2,322,000 (20,530,000)
Cash, cash equivalents and restricted cash at beginning of year 27,213,000 24,891,000 45,421,000
Cash, cash equivalents and restricted cash at end of year 49,967,000 27,213,000 24,891,000
Supplemental disclosure of cash flow information      
Cash paid during the year for interest 6,583,000    
Accrual for litigation settlement and insurance recovery (Note 9)     4,975,000
Release of accrual for litigation settlement and insurance recovery (Note 9)   4,975,000  
Non-cash investing and financing activities:      
Disposal of fully depreciated property and equipment 199,000 $ 86,000 2,354,000
Non-cash acquisition of technology license $ 12,773,000    
Astra Zeneca      
Supplemental disclosure of cash flow information      
Return of unused development funding to AstraZeneca AB     7,200,000
Milestone payment from AstraZeneca AB     $ 7,200,000